The Long Run with Luke Timmerman podcast

Ep199: Martin Burke on Making Small Molecule Medicines for the AI Era

21.4.2026

The Long Run with Luke Timmerman

0:00

1:10:08

Marty Burke, a professor of chemistry at the University of Illinois and co-founder of Excelsior Sciences, on making small molecule synthesis more automated for AI.

Weitere Episoden von „The Long Run with Luke Timmerman“

Ep199: Martin Burke on Making Small Molecule Medicines for the AI Era
21.4.2026
1:10:08
Marty Burke, a professor of chemistry at the University of Illinois and co-founder of Excelsior Sciences, on making small molecule synthesis more automated for AI.
Ep198: Abbas Kazimi on Computation and Culture for Drug Discovery
7.4.2026
1:16:43
Abbas Kazimi, CEO of Boston-based Nimbus Therapeutics, on computation and culture for drug discovery.
Verpasse keine Episode von “The Long Run with Luke Timmerman” und abonniere ihn in der kostenlosen GetPodcast App.
Ep197: Viswa Colluru on Discovering Drugs Inspired by Mother Nature
31.3.2026
1:16:57
Viswa Colluru, founder and CEO of Boulder, Colo.-based Enveda, on drug discovery with a chemistry platform inspired by natural products.
Ep196: Otello Stampacchia on Europe's Biotech Crisis
17.3.2026
1:03:17
Otello Stampacchia, founder and managing director of Omega Funds, on attempting to reform Europe's biotech investment climate.
Ep195: Ken Song on T-cell Engagers for Autoimmune Diseases
3.3.2026
1:05:45
Ken Song, CEO of San Diego-based Candid Therapeutics, on developing bispecific T-cell engaging antibodies for autoimmune disease.
Ep194: Ansu Satpathy on Cancer and Autoimmune Drug Discovery
17.2.2026
1:08:54
Ep194: Ansu Satpathy on Cancer and Autoimmune Drug Discovery by Timmerman Report
Ep193: Ron Renaud on Helping People Lose Weight With GLP-1 Medicines
22.1.2026
1:05:10
Ron Renaud, CEO of Waltham, Mass.-based Kailera Therapeutics, on developing GLP-1 based medicines to help people lose weight and live healthier lives.
Ep192: Kate Haviland on Following the Science to Precision Immunology
8.1.2026
1:26:06
Kate Haviland, former CEO of Blueprint Medicines, on how the company transitioned to a precision immunology company and was acquired by Sanofi for $9.5 billion.
Ep191: Emily Conley on Small Molecules to Correct a Rare Kidney Disease
15.12.2025
1:07:34
Emily Conley, CEO of Berkeley, CA-based Renasant Bio, on developing small molecule correctors and potentiators for autosomal dominant polycystic kidney disease (ADPKD).
Ep190: Neil Kumar on Building a Rare Disease Drug Company
20.11.2025
1:13:12
Neil Kumar is founder and CEO of Palo Alto, Calif.-based BridgeBio Pharma, a rare disease drug developer.

Weitere Episoden

Hol dir die ganze Welt der Podcasts mit der kostenlosen GetPodcast App.

Abonniere alle deine Lieblingspodcasts, höre Episoden auch offline und erhalte passende Empfehlungen für Podcasts, die dich wirklich interessieren.

Ein Unternehmen von

Ep199: Martin Burke on Making Small Molecule Medicines for the AI Era

The Long Run with Luke Timmerman

Weitere Episoden von „The Long Run with Luke Timmerman“

Ep199: Martin Burke on Making Small Molecule Medicines for the AI Era

Ep198: Abbas Kazimi on Computation and Culture for Drug Discovery

Ep197: Viswa Colluru on Discovering Drugs Inspired by Mother Nature

Ep196: Otello Stampacchia on Europe's Biotech Crisis

Ep195: Ken Song on T-cell Engagers for Autoimmune Diseases

Ep194: Ansu Satpathy on Cancer and Autoimmune Drug Discovery

Ep193: Ron Renaud on Helping People Lose Weight With GLP-1 Medicines

Ep192: Kate Haviland on Following the Science to Precision Immunology

Ep191: Emily Conley on Small Molecules to Correct a Rare Kidney Disease

Ep190: Neil Kumar on Building a Rare Disease Drug Company